Impact of Rapid Multiplex Point of Care Testing on Antibiotic PrescribingRapid testing shows mixed results for reducing common antibiotic use

This randomized clinical trial evaluated the impact of rapid multiplex microbiological point-of-care testing (RM-POCT) on prescribing patterns for acute respiratory tract infections. The study enrolled 552 patients, including both children and adults, who presented to primary care settings where antibiotic treatment was being considered. The intervention involved a multiplex test capable of detecting 19 viral pathogens and 4 atypical bacteria to guide clinical decision-making.

The primary outcome measure was the rate of same-day antibiotic prescribing. In the overall study population, there was no statistically significant difference in prescription rates between the RM-POCT group and the usual care group. Both cohorts showed a 45% rate of immediate antibiotic administration, suggesting that the mere presence of rapid testing did not automatically decrease prescribing across the entire patient demographic.

However, granular analysis revealed significant interactions within specific subgroups. For patients where a viral pathogen was successfully detected by the RM-POCT, there was a notable reduction in same-day antibiotic prescriptions (OR 0.35). This suggests that when clinicians have definitive evidence of a viral etiology, they are more likely to withhold antibiotics compared to those without such data.

Another significant finding occurred among patients with chronic lung disease. In this specific cohort, the use of RM-POCT was associated with lower rates of same-day antibiotic prescribing (OR 0.55). This indicates that for high-risk populations where clinical uncertainty often leads to prophylactic prescribing, rapid diagnostic data may provide enough clarity to manage treatment more conservatively.

In contrast, several subgroups showed no change in prescription behavior despite the intervention. Specifically, among children under 16 years of age and in cases where there was initial clinician disagreement regarding the necessity of antibiotics, the use of RM-POCT did not alter prescribing rates. These results suggest that certain clinical scenarios may be influenced by other factors, such as parental pressure or standard pediatric protocols.

Regarding patient outcomes, the study assessed reported symptom severity from days 2 to 4 post-presentation. No significant difference in symptoms was observed between the intervention and control groups. This confirms that while RM-POCT influences clinical decision-making in specific contexts, it does not negatively impact patient experience or safety regarding symptomatic progression.

Clinicians should note that while RM-POCT did not demonstrate a universal reduction in antibiotic use, its utility is most evident in cases of confirmed viral infections and for patients with chronic underlying conditions. The technology serves as a targeted tool rather than a blanket solution for reducing antimicrobial consumption. Implementation may require specific clinical protocols to maximize the impact on prescribing behavior.